← All trials
NCT05169684
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 14, 2022
- Primary completion
- Feb 12, 2026
- Completion date
- Feb 13, 2026
- First posted
- Dec 27, 2021
- Last posted
- Aug 3, 2022
- Enrollment
- 204
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bristol-Myers SquibbLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.